UPDATE : Thursday, August 22, 2019
상단여백
294 shareholders file suit against Kolon TissueGene for damage compensation by Jeong Sae-im 2019-06-14 10:51
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe by Lee Han-soo 2019-06-13 16:10
Kolon TissueGene CEO resigns by Jeong Sae-im 2019-06-07 15:35
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’ by Lee Han-soo, KBR correspondent 2019-06-04 14:17
Kolon’s minority shareholders demand over ₩25 billion in damage by Jeong Sae-im 2019-06-03 14:53
라인
Invossa inventor sold Kolon shares at highest value by Jeong Sae-im 2019-06-03 14:52
Until when will Kolon keep lying about Invossa? by Jeong Sae-im 2019-05-31 14:59
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug by Jeong Sae-im 2019-05-31 14:59
Announcement of Invossa license revocation was ‘procedural breach’: Kolon by Jeong Sae-im 2019-05-30 13:28
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy by Kim Yun-mi 2019-05-29 12:35
라인
Invossa poses almost no safety threat: regulator by Lee Hye-seon 2019-05-28 16:02
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar by Lee Han-soo 2019-05-27 15:52
‘Shareholders can surely win lawsuit against Kolon’ by Jeong Sae-im 2019-05-24 19:34
‘Kolon’s extra data insufficient to explain Invossa mislabeling’ by Lee Hye-seon 2019-05-23 14:51
Prosecutors seek arrest warrant of Samsung BioLogics CEO by Lee Han-soo 2019-05-23 11:19
라인
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients by Jeong Sae-im 2019-05-22 11:59
Legislator, activists call for revoking Invossa license, conducting probes by Jeong Sae-im 2019-05-21 16:03
Kolon to follow 3,700 Invossa-treated patients for 15 years by Jeong Sae-im 2019-05-17 15:38
Will Celltrion CEO’s bet on ‘bio valley’ pay off? by Jeong Sae-im 2019-05-17 13:21
CHA Biotech’s operating income plunges 92% in Q1 by Jeong Sae-im 2019-05-16 13:41
여백
여백
여백
Back to Top